[VEGF and survival of patients with lung cancer: a systematic literature review and meta-analysis].

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Revue des maladies respiratoires

• Publication date

  2002-10-01

• Fields of study

  Medicine

• Identifiers
  PMID 12473944
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The role of mitomycin in the treatment of non-small cell lung cancer: a systematic review with meta-analysis of the literature

  2001cited by this paper
• Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis.

  2001cited by this paper
• Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer.

  2000cited by this paper
• Increased vascular endothelial growth factor and vascular endothelial growth factor-c and decreased nm23 expression associated with microdissemination in the lymph nodes in stage I non-small cell lung cancer.

  2000cited by this paper
• Regulation of angiogenesis via vascular endothelial growth factor receptors.

  2000cited by this paper
• Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer

  2000cited by this paper
• Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer.

  2000cited by this paper
• Prognostic value of vascular endothelial growth factor expression in primary lung carcinoma.

  2000cited by this paper
• Prognostic factors for patients with small cell lung carcinoma

  2000cited by this paper
• Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma.

  2000cited by this paper
• A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis.

  2000cited by this paper
• Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas

  1999cited by this paper
• Tumor angiogenesis and recurrence in stage I non-small cell lung cancer.

  1999cited by this paper
• Immunohistochemical study on tumor angiogenic factors in non-small cell lung cancer.

  1999cited by this paper
• Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas.

  1998cited by this paper
• Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

  1998cited by this paper
• Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma.

  1998cited by this paper
• Expression of cell-associated isoform of vascular endothelial growth factor 189 and its prognostic relevance in non-small cell lung cancer.

  1998cited by this paper
• [Critical review of the randomized trials assessing the role of adjuvant thoracic irradiation and chemotherapy in the treatment of limited-stage small cell lung cancer].

  1998cited by this paper
• Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients.

  1998cited by this paper
• Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma.

  1998cited by this paper
• Bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung carcinoma.

  1998cited by this paper
• High pre‐treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small‐cell lung cancer

  1998cited by this paper
• Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer.

  1998cited by this paper
• Prognostic value of vascular endothelial growth factor and its receptor Flt‐1 in squamous cell lung cancer

  1997cited by this paper
• Vascular endothelial growth factor and its receptor correlate with angiogenesis and survival in pulmonary adenocarcinoma.

  1997cited by this paper
• Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma.

  1997cited by this paper
• Molecular mechanisms of blood vessel formation.

  1997cited by this paper
• Vascular endothelial growth factor-121 mRNA expression and neomicrovessel density in primary lung cancer.

  1996cited by this paper
• TUMOUR ANGIOGENESIS

  1996cited by this paper
• Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer.

  1996cited by this paper
• Vascular endothelial growth factor.

  1996cited by this paper
• Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party.

  1995cited by this paper
• Vascular endothelial growth-factor expression and angiogenesis in nonsmall cell lung carcinomas.

  1995cited by this paper
• Clinical prognostic significance of tumour angiogenesis.

  1994cited by this paper
• Relation of neovascularisation to metastasis of non-small-cell lung cancer.

  1992cited by this paper
• The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA.

  1991cited by this paper
• The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing.

  1991cited by this paper
• Beta blockade during and after myocardial infarction: an overview of the randomized trials.

  1985cited by this paper

• Vascular endothelial growth factor levels in tuberculosis: A systematic review and meta-analysis

  2022cites this paper
• Hypoxia in Lung Cancer Management: A Translational Approach

  2021cites this paper
• MicroRNA-4316 inhibits gastric cancer proliferation and migration via directly targeting VEGF-A

  2020influential citation
• Evaluation of Detection Methods and Values of Circulating Vascular Endothelial Growth Factor in Lung Cancer

  2018cites this paper
• Clinical Significance of Serum Vascular Endothelial Growth Factor Levels in Patients with Advanced Non-Small Cell Lung cancer

  2017cites this paper
• Elevated serum levels of vascular endothelial growth factor predict a poor prognosis of platinum-based chemotherapy in non-small cell lung cancer

  2017cites this paper
• MicroRNA-34a: A Key Regulator in the Hallmarks of Renal Cell Carcinoma

  2017cites this paper
• Ramucirumab in the treatment of non-small cell lung cancer

  2017cites this paper
• Response Assessment of 68Ga-DOTA-E-[c(RGDfK)]2 PET/CT in Lung Adenocarcinoma Patients Treated with Nintedanib Plus Docetaxel

  2017influential citation
• eview irected Therapies in Lung Cancer : New Hope ?

  2017cites this paper
• MicroRNA-29c functions as a tumor suppressor by targeting VEGFA in lung adenocarcinoma

  2017influential citation
• GDNF secreted from adipose-derived stem cells stimulates VEGF-independent angiogenesis

  2016cites this paper
• Distinct patterns of angiogenic factor expression as a predictive factor of response to chemotherapy in stage IIIA non-small-cell lung cancer patients.

  2016cites this paper
• The Importance of Vascular Endothelial Growth Factor as a Marker of Angiogenesis and Lymphangiogenesis in Non-small Cell Lung Cancer

  2015cites this paper
• Correlation between expression and significance of δ-catenin, CD31, and VEGF of non-small cell lung cancer.

  2015cites this paper
• Expression and clinical significance of vascular endothelial growth factor and fms-related tyrosine kinase 1 in colorectal cancer.

  2015cites this paper
• Correlation between expression and significance of δ-catenin , CD 31 , and VEGF of non-small cell lung cancer

  2015cites this paper
• Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis

  2015cites this paper
• Anti-angiogenic drugs and biomarkers in non-small-cell lung cancer: a 'hard days night'.

  2014cites this paper
• Targeting multiple angiogenic pathways simultaneously: experience with nintedanib in non-small-cell lung cancer.

  2014cites this paper
• Nintedanib for the treatment of non-small-cell lung cancer

  2014cites this paper
• Prognostic Value of Human Equilibrative NucleosideTransporter1 in Pancreatic Cancer Receiving Gemcitabin-Based Chemotherapy: A Meta-Analysis

  2014cites this paper
• Analysis of Expression of Vascular Endothelial Growth Factor A and Hypoxia Inducible Factor-1alpha in Patients Operated on Stage I Non-Small-Cell Lung Cancer

  2014cites this paper
• Prognostic role of microvessel density in patients with renal cell carcinoma: a meta-analysis.

  2014cites this paper
• Vascular endothelial growth factor (VEGF) −2578C/A and −460C/T gene polymorphisms and lung cancer risk: a meta-analysis involving 11 case–control studies

  2013cites this paper
• VEGF and TSP1 levels correlate with prognosis in advanced non-small cell lung cancer

  2013cites this paper
• Lung Cancer: A Classic Example of Tumor Escape and Progression While Providing Opportunities for Immunological Intervention

  2012cites this paper
• Lymphatic microvessel density and vascular endothelial growth factor-C and -D as prognostic factors in breast cancer: a systematic review and meta-analysis of the literature

  2012cites this paper
• Directed therapies in lung cancer: new hope?

  2012cites this paper
• Safety profile and tolerability of antiangiogenic agents in non-small-cell lung cancer.

  2012cites this paper
• Targeting VEGF in lung cancer

  2012cites this paper
• Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer.

  2012cites this paper
• Prognostic and predictive factors for lung cancer

  2012cites this paper
• Lung Cancer: A Classic Example of Tumor Escape and Progression While Providing Opportunities for Immunological Intervention Journal Issue: Clinical and Developmental Immunology, 2012 Author:

  2012cites this paper
• Directed Therapies in Lung Cancer: New Hope?

  2012cites this paper
• Terapias dirigidas en el cáncer de pulmón: ¿una nueva esperanza?

  2012cites this paper
• Lymphatic microvessel density as a prognostic factor in non-small cell lung carcinoma: a meta-analysis of the literature

  2011cites this paper
• Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC

  2011cites this paper
• Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer

  2011influential citation
• Emerging antiangiogenic therapies for non-small-cell lung cancer

  2011cites this paper
• Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables

  2011cites this paper
• [Molecular targeted therapies in small-cell lung cancer].

  2010cites this paper
• Targeting Angiogenesis in Non-Small Cell Lung Cancer (NSCLC)

  2010cites this paper
• Current data on predictive markers for anti-angiogenic therapy in thoracic tumours

  2010cites this paper
• HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer

  2010cites this paper
• Update on nonsmall cell lung cancer

  2010cites this paper
• Molecular Prognostic and Predictive Markers in Lung Cancer

  2009cites this paper
• Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer

  2009cites this paper
• Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Lung Cancer: A Systematic Review with Meta-Analysis

  2009cites this paper
• [Bevacizumab and non-small cell lung cancer: a new step?].

  2009cites this paper
• Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer.

  2009cites this paper
• Prognostic and Predictive Significance of Surrogate Biomarkers of Angiogenesis.

  2008cites this paper
• [Tumor vasculature as a therapeutic target in non-small cell lung cancer].

  2008cites this paper
• The Impact of Additional Prognostic Factors on Survival and their Relationship with the Anatomical Extent of Disease Expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the Proposals for the 7th Edition

  2008cites this paper
• The comparison of prognostic value of VEGF and MMP-9 in non-small cell lung cancer during three-year observation after anti-tumour treatment

  2008cites this paper
• Fundamentals of Cancer Cell Biology and Molecular Targeting

  2008cites this paper
• Targeting blood vessels for the treatment of non-small cell lung cancer.

  2008cites this paper
• A daganatos érhálózat mint terápiás célpont nem kissejtes tüdőrákban

  2008cites this paper
• [Are antiangiogenic antibodies universal for solid tumor?].

  2007cites this paper
• Potential role of multi-targeted tyrosine kinase inhibitors in non-small-cell lung cancer.

  2007cites this paper
• [Angiogenesis and lung cancer].

  2007cites this paper
• Inhibition of angiogenesis in the treatment of non‐small cell lung cancer

  2007cites this paper
• Traitements antiangiogéniques au cours des cancers bronchiques Antiangiogenic treatments in lung cancer

  2007cites this paper
• Serum Vascular Endothelial Growth Factor (VEGF) and Bcl-2 Levels in Advanced Stage Non-Small Cell Lung Cancer

  2006cites this paper
• Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood.

  2006cites this paper
• Thyroid transcription factor 1--a new prognostic factor in lung cancer: a meta-analysis.

  2006cites this paper
• Antiangiogenic drugs in non-small cell lung cancer treatment

  2006cites this paper
• Benefit of a combined treatment of cryotherapy and chemotherapy on tumour growth and late cryo-induced angiogenesis in a non-small-cell lung cancer model.

  2006cites this paper
• Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer.

  2006cites this paper
• Anticorps anti-VEGF: un emploi universel?

  2006cites this paper
• Has Cox-2 a prognostic role in non-small-cell lung cancer? A systematic review of the literature with meta-analysis of the survival results

  2006cites this paper
• Angiogenesis and lung cancer: prognostic and therapeutic implications.

  2005cites this paper
• VEGF-targeted therapy: therapeutic potential and recent advances.

  2005cites this paper
• Expression of Placental Growth Factor Gene in Lung Cancer

  2004cites this paper
• Marcadores tumorales y cncer de pulmn. Qu hay de nuevo

  2004cites this paper
• Targeting Aberrant Signal Transduction Pathways in Lung Cancer

  2004cites this paper
• The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

  2004cites this paper
• Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis

  2004cites this paper
• Antiangiogenic drugs and current strategies for the treatment of lung cancer.

  2004cites this paper
• [New biological markers of lung cancer: toward targeted biotherapies?].

  2002cites this paper